IMUX

Business Context and Reporting Period

Company: Immunic, Inc. (IMUX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Immunic is a late-stage biotechnology company developing novel oral therapies for neurologic and autoimmune diseases. Its lead program, vidofludimus calcium (IMU-838), is in Phase 3 clinical development for relapsing multiple sclerosis (RMS). Other programs include IMU-856 (gastrointestinal diseases) and IMU-381 (preclinical). The Company has no approved products and has not generated product revenue.

Key Financial Metrics

Liquidity: As of March 31, 2026, the Company held approximately $186.6 million in cash and cash equivalents, sufficient to fund operations for more than 12 months.

Material Changes vs. Prior Period

• Financing Activity: The Company completed a $200 million private placement in February 2026 (net proceeds of $187.3 million), significantly increasing cash reserves from $15.5 million at year-end 2025 to $186.6 million.
• Operating Expenses: Total operating expenses increased 24% to $33.2 million from $26.8 million year-over-year.
  • R&D Expenses: Increased 19% to $25.6 million, driven by a $2.9 million increase in external development costs for the vidofludimus calcium program.
  • G&A Expenses: Increased 44% to $7.6 million, primarily due to a $2.0 million increase in personnel expenses, largely attributed to non-cash stock-based compensation.
• Stock-Based Compensation: Total stock-based compensation expense more than doubled to $4.5 million from $2.0 million, driven by new grants and liability revaluations for Stock Appreciation Rights (SARs).
• Other Income: Other income (expense) decreased by $1.3 million, primarily due to the absence of a $1.1 million German government research grant recognized in Q1 2025.

Guidance, Outlook, and Material Events

• Reverse Stock Split: A 1-for-10 reverse stock split was approved by stockholders and became effective on April 27, 2026. All share data in the filing has been restated to reflect this split.
• CEO Transition: The Company initiated a search for a new CEO with commercial expertise. Current CEO Dr. Daniel Vitt will transition to a senior executive role focused on scientific strategy. A retention bonus of $670,000 was agreed upon for Dr. Vitt.
• Key Personnel Changes: Michael A. Panzara, M.D., was appointed Chief Medical Officer effective April 24, 2026. Andreas Muehler, M.D., resigned as CMO and transitioned to a consulting role.
• Royalty Exchange: In conjunction with the February 2026 financing, certain Series B warrant holders exchanged 5.1 million warrants for a 5% synthetic royalty on future sales of vidofludimus calcium.
• Clinical Outlook: Top-line data for the Phase 3 ENSURE trials (vidofludimus calcium in RMS) is expected by the end of 2026. Enrollment for both trials was completed in June 2025.
• Risks: The Company remains dependent on successful clinical trial outcomes and regulatory approvals. It has no revenue and expects to incur significant losses in the foreseeable future. Future funding may be required.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $186.6 million cash balance against projected burn rates for the remainder of 2026 and 2027, particularly given the upcoming Phase 3 data readout.
• Dilution Impact: Assess the dilutionary effect of the 22.9 million pre-funded warrants issued in the February 2026 offering and the 3.4 million Series B warrants remaining outstanding.
• Royalty Obligation: Review the terms of the 5% synthetic royalty on vidofludimus calcium sales granted to Series B warrant holders and its potential impact on future net margins.
• Stock-Based Compensation: Monitor the trajectory of stock-based compensation expenses, which rose significantly in Q1 2026 due to SAR liability revaluations and new grants.
• Leadership Stability: Track the progress of the CEO search and the integration of the new Chief Medical Officer to ensure strategic continuity.